The effects of the oral supplementation of L‐Cystine associated with reduced L‐Glutathione‐GSH on human skin pigmentation: a randomized, double‐blinded, benchmark‐ and placebo‐controlled clinical trial

Background Glutathione has become a potential skin‐lightening ingredient after the discovery of its anti‐melanogenic properties. Various mechanisms of action have been considered to explain this property, one of them being the skewing of the melanin synthesis pathway toward the production of lighter...

Full description

Saved in:
Bibliographic Details
Published inJournal of cosmetic dermatology Vol. 21; no. 2; pp. 802 - 813
Main Authors Duperray, Joël, Sergheraert, Renaud, Chalothorn, Kunyanatt, Tachalerdmanee, Preeyanuch, Perin, Fabrice
Format Journal Article
LanguageEnglish
Published England 01.02.2022
Subjects
Online AccessGet full text
ISSN1473-2130
1473-2165
1473-2165
DOI10.1111/jocd.14137

Cover

Abstract Background Glutathione has become a potential skin‐lightening ingredient after the discovery of its anti‐melanogenic properties. Various mechanisms of action have been considered to explain this property, one of them being the skewing of the melanin synthesis pathway toward the production of lighter pheomelanin instead of darker eumelanin, consequently producing a lightening effect. Aims To evaluate the skin lightening and anti‐dark spot effects of oral supplementation with L‐Cystine associated with L‐Glutathione as compared to placebo and benchmark. Methods Effects of this L‐Cystine‐L‐Glutathione oral combination were investigated in a 12‐week randomized, double‐blind, parallel‐group, benchmark‐ and placebo‐controlled trial involving 124 Asian female subjects. Women were randomly allocated into 4 equal groups (500 mg L‐Cystine and 250 mg L‐Glutathione, 250 mg reduced L‐Glutathione, 500 mg L‐Cystine, or a placebo, daily). Skin color was measured at baseline, after 6 and 12 weeks by spectrophotometry. Size and color of facial dark spots were determined from digital photographs. Results A significant skin lightening was observed after 12 weeks of oral supplementation with L‐Cystine associated with L‐Glutathione. This combination also induced a significant reduction in the size of facial dark spots after 6 and 12 weeks. It is noteworthy that the observed effects were not only significantly better than those obtained with placebo, but also with L‐Cystine alone or L‐Glutathione alone. Conclusion The daily oral administration of 500 mg L‐Cystine and 250 mg L‐Glutathione during 12 weeks was a safe treatment to effectively lighten the skin and reduce the size of facial dark spots of Asian women.
AbstractList Glutathione has become a potential skin-lightening ingredient after the discovery of its anti-melanogenic properties. Various mechanisms of action have been considered to explain this property, one of them being the skewing of the melanin synthesis pathway toward the production of lighter pheomelanin instead of darker eumelanin, consequently producing a lightening effect.BACKGROUNDGlutathione has become a potential skin-lightening ingredient after the discovery of its anti-melanogenic properties. Various mechanisms of action have been considered to explain this property, one of them being the skewing of the melanin synthesis pathway toward the production of lighter pheomelanin instead of darker eumelanin, consequently producing a lightening effect.To evaluate the skin lightening and anti-dark spot effects of oral supplementation with L-Cystine associated with L-Glutathione as compared to placebo and benchmark.AIMSTo evaluate the skin lightening and anti-dark spot effects of oral supplementation with L-Cystine associated with L-Glutathione as compared to placebo and benchmark.Effects of this L-Cystine-L-Glutathione oral combination were investigated in a 12-week randomized, double-blind, parallel-group, benchmark- and placebo-controlled trial involving 124 Asian female subjects. Women were randomly allocated into 4 equal groups (500 mg L-Cystine and 250 mg L-Glutathione, 250 mg reduced L-Glutathione, 500 mg L-Cystine, or a placebo, daily). Skin color was measured at baseline, after 6 and 12 weeks by spectrophotometry. Size and color of facial dark spots were determined from digital photographs.METHODSEffects of this L-Cystine-L-Glutathione oral combination were investigated in a 12-week randomized, double-blind, parallel-group, benchmark- and placebo-controlled trial involving 124 Asian female subjects. Women were randomly allocated into 4 equal groups (500 mg L-Cystine and 250 mg L-Glutathione, 250 mg reduced L-Glutathione, 500 mg L-Cystine, or a placebo, daily). Skin color was measured at baseline, after 6 and 12 weeks by spectrophotometry. Size and color of facial dark spots were determined from digital photographs.A significant skin lightening was observed after 12 weeks of oral supplementation with L-Cystine associated with L-Glutathione. This combination also induced a significant reduction in the size of facial dark spots after 6 and 12 weeks. It is noteworthy that the observed effects were not only significantly better than those obtained with placebo, but also with L-Cystine alone or L-Glutathione alone.RESULTSA significant skin lightening was observed after 12 weeks of oral supplementation with L-Cystine associated with L-Glutathione. This combination also induced a significant reduction in the size of facial dark spots after 6 and 12 weeks. It is noteworthy that the observed effects were not only significantly better than those obtained with placebo, but also with L-Cystine alone or L-Glutathione alone.The daily oral administration of 500 mg L-Cystine and 250 mg L-Glutathione during 12 weeks was a safe treatment to effectively lighten the skin and reduce the size of facial dark spots of Asian women.CONCLUSIONThe daily oral administration of 500 mg L-Cystine and 250 mg L-Glutathione during 12 weeks was a safe treatment to effectively lighten the skin and reduce the size of facial dark spots of Asian women.
Background Glutathione has become a potential skin‐lightening ingredient after the discovery of its anti‐melanogenic properties. Various mechanisms of action have been considered to explain this property, one of them being the skewing of the melanin synthesis pathway toward the production of lighter pheomelanin instead of darker eumelanin, consequently producing a lightening effect. Aims To evaluate the skin lightening and anti‐dark spot effects of oral supplementation with L‐Cystine associated with L‐Glutathione as compared to placebo and benchmark. Methods Effects of this L‐Cystine‐L‐Glutathione oral combination were investigated in a 12‐week randomized, double‐blind, parallel‐group, benchmark‐ and placebo‐controlled trial involving 124 Asian female subjects. Women were randomly allocated into 4 equal groups (500 mg L‐Cystine and 250 mg L‐Glutathione, 250 mg reduced L‐Glutathione, 500 mg L‐Cystine, or a placebo, daily). Skin color was measured at baseline, after 6 and 12 weeks by spectrophotometry. Size and color of facial dark spots were determined from digital photographs. Results A significant skin lightening was observed after 12 weeks of oral supplementation with L‐Cystine associated with L‐Glutathione. This combination also induced a significant reduction in the size of facial dark spots after 6 and 12 weeks. It is noteworthy that the observed effects were not only significantly better than those obtained with placebo, but also with L‐Cystine alone or L‐Glutathione alone. Conclusion The daily oral administration of 500 mg L‐Cystine and 250 mg L‐Glutathione during 12 weeks was a safe treatment to effectively lighten the skin and reduce the size of facial dark spots of Asian women.
Glutathione has become a potential skin-lightening ingredient after the discovery of its anti-melanogenic properties. Various mechanisms of action have been considered to explain this property, one of them being the skewing of the melanin synthesis pathway toward the production of lighter pheomelanin instead of darker eumelanin, consequently producing a lightening effect. To evaluate the skin lightening and anti-dark spot effects of oral supplementation with L-Cystine associated with L-Glutathione as compared to placebo and benchmark. Effects of this L-Cystine-L-Glutathione oral combination were investigated in a 12-week randomized, double-blind, parallel-group, benchmark- and placebo-controlled trial involving 124 Asian female subjects. Women were randomly allocated into 4 equal groups (500 mg L-Cystine and 250 mg L-Glutathione, 250 mg reduced L-Glutathione, 500 mg L-Cystine, or a placebo, daily). Skin color was measured at baseline, after 6 and 12 weeks by spectrophotometry. Size and color of facial dark spots were determined from digital photographs. A significant skin lightening was observed after 12 weeks of oral supplementation with L-Cystine associated with L-Glutathione. This combination also induced a significant reduction in the size of facial dark spots after 6 and 12 weeks. It is noteworthy that the observed effects were not only significantly better than those obtained with placebo, but also with L-Cystine alone or L-Glutathione alone. The daily oral administration of 500 mg L-Cystine and 250 mg L-Glutathione during 12 weeks was a safe treatment to effectively lighten the skin and reduce the size of facial dark spots of Asian women.
Author Chalothorn, Kunyanatt
Duperray, Joël
Sergheraert, Renaud
Tachalerdmanee, Preeyanuch
Perin, Fabrice
Author_xml – sequence: 1
  givenname: Joël
  orcidid: 0000-0003-1941-4847
  surname: Duperray
  fullname: Duperray, Joël
  email: jduperray@bcf-lifesciences.com
  organization: BCF Life Sciences
– sequence: 2
  givenname: Renaud
  surname: Sergheraert
  fullname: Sergheraert, Renaud
  organization: BCF Life Sciences
– sequence: 3
  givenname: Kunyanatt
  surname: Chalothorn
  fullname: Chalothorn, Kunyanatt
  organization: Spincontrol Asia Co., Ltd
– sequence: 4
  givenname: Preeyanuch
  surname: Tachalerdmanee
  fullname: Tachalerdmanee, Preeyanuch
  organization: Spincontrol Asia Co., Ltd
– sequence: 5
  givenname: Fabrice
  surname: Perin
  fullname: Perin, Fabrice
  organization: Spincontrol Asia Co., Ltd
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33834608$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtu1TAUhi1URB8wYQHIQ4S4xY88maELtKArdUAZW459Qtw6drAdVZcRS2BzbICV4JC2A4TwxP6Pv__48R-jA-cdIPSUklOax6srr_QpLSivH6AjWtR8w2hVHtyvOTlExzFeEULrlpaP0CHnDS8q0hyhn5cDYOh7UCli3-OUpQ_S4jhPk4URXJLJeLfs7X59_7Hdx2QcYBmjV0Ym0PjGpAEH0LPKYmHO7JxNQ3bBoj6d4-wf5lE6HK-Nw5P5ct_3NZY4SKf9aL6Bfom1nzu72DprnF4qHTg1jDJc5yLOJJ6sVND5LJV3KXhr87kq40ble6dgpH2MHvbSRnhyO5-gz-_fXW7PN7uLsw_bN7uN4qytN1o20OuqBs4p7UuiqoqUBdclK1VNaEnquq0q2uZRtk3RsZaxopNNCaovetbxE_R87TsF_3WGmMRoogJrpQM_R8FKShlv65Zl9NktOncjaDEFkx-1F3dRZICsgAo-xgC9UGb9oxSksYISsaQtlrTFn7Sz5cVflruu_4TpCt8YC_v_kOLjxfbt6vkNCb7DjA
CitedBy_id crossref_primary_10_1016_j_indcrop_2024_120363
crossref_primary_10_1039_D2TA08783A
crossref_primary_10_1002_anie_202312728
crossref_primary_10_3390_antiox11030503
crossref_primary_10_1111_1365_2435_14209
crossref_primary_10_1186_s43094_023_00523_y
crossref_primary_10_1097_JTCCM_D_24_00030
crossref_primary_10_1111_jdv_19717
crossref_primary_10_1111_jocd_15242
crossref_primary_10_7759_cureus_78045
crossref_primary_10_1038_s41467_022_34716_5
crossref_primary_10_1016_j_arr_2025_102712
crossref_primary_10_1111_jocd_16626
crossref_primary_10_7759_cureus_40892
crossref_primary_10_1016_j_ad_2022_09_014
crossref_primary_10_1002_ange_202312728
crossref_primary_10_3390_cosmetics12010027
crossref_primary_10_3390_cosmetics10050143
crossref_primary_10_1016_j_ad_2022_09_021
crossref_primary_10_1111_ijd_17535
crossref_primary_10_1136_lupus_2024_001401
crossref_primary_10_52660_JKSC_2023_29_6_1496
Cites_doi 10.1111/1523-1747.ep12340980
10.1111/ijd.12999
10.3109/09546631003801619
10.1111/j.1755-148X.2009.00610.x
10.4103/0378-6323.179088
10.1002/jbio.200900066
10.1111/1523-1747.ep12365591
10.2147/CCID.S128339
10.1111/j.1468-2494.2010.00616.x
10.1111/1523-1747.ep12277369
10.1111/j.1600-0749.2006.00293.x
10.9734/EJNFS/2019/45634
10.1111/pcmr.12393
10.1007/s00726-011-0867-5
10.1590/S0365-05962013000100009
10.1111/pcmr.12235
10.1034/j.1600-0749.2003.00082.x
10.1111/1523-1747.ep12371709
10.1002/mnfr.201500031
10.1364/OL.28.000114
10.1111/jocd.12910
10.1038/sj.jid.5700683
10.2147/CCID.S115519
10.1093/jn/134.3.489
10.1016/j.jaad.2018.08.035
10.1364/OE.17.014599
10.4103/0378-6323.120752
10.1097/MCO.0b013e32834c1780
10.1046/j.1467-2494.2003.00182.x
10.1111/j.1467-2494.2005.00235.x
10.1002/lsm.20219
10.1111/pcmr.12121
ContentType Journal Article
Copyright 2021 Wiley Periodicals LLC
2021 Wiley Periodicals LLC.
Copyright_xml – notice: 2021 Wiley Periodicals LLC
– notice: 2021 Wiley Periodicals LLC.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1111/jocd.14137
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1473-2165
EndPage 813
ExternalDocumentID 33834608
10_1111_jocd_14137
JOCD14137
Genre article
Randomized Controlled Trial
Journal Article
GrantInformation_xml – fundername: BCF Life Sciences
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
1OC
24P
29K
31~
33P
36B
3SF
4.4
50Y
50Z
52M
52O
52T
52U
52V
52W
53G
5GY
5HH
5VS
702
7PT
7X7
8-0
8-1
8-3
8-4
8-5
8FI
8FJ
930
A01
A03
AAESR
AAEVG
AAHHS
AAKAS
AANHP
AAONW
AASGY
AAXRX
AAZKR
ABCUV
ABDBF
ABJNI
ABPVW
ABUWG
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCMX
ACCZN
ACGFS
ACMXC
ACPOU
ACRPL
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADPDF
ADXAS
ADZCM
ADZMN
AEEZP
AEGXH
AEIMD
AENEX
AEQDE
AEUQT
AFBPY
AFEBI
AFGKR
AFKRA
AFPWT
AFZJQ
AIACR
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BENPR
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
C45
CAG
CCPQU
COF
CS3
D-6
D-7
D-E
D-F
D-I
DCZOG
DPXWK
DRFUL
DRMAN
DRSTM
EAD
EAP
EBD
EBS
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F21
F5P
FEDTE
FUBAC
FYUFA
G-S
G.N
GODZA
H.X
HF~
HMCUK
HVGLF
HZ~
IHE
KBYEO
LATKE
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
MY~
N04
N05
NF~
O66
O9-
OIG
OVD
OVEED
P2P
P2W
P2X
P2Z
P4B
P4D
PIMPY
Q.N
QB0
R.K
ROL
RX1
SUPJJ
SV3
TEORI
TUS
UB1
UKHRP
V8K
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WVDHM
YFH
YUY
ZZTAW
~IA
~WT
AAYXX
AGQPQ
CITATION
PHGZM
PHGZT
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c3297-da8efd67e3311f50c660543d525c7015077966199995984b29224ba85ecf4f2b3
ISSN 1473-2130
1473-2165
IngestDate Fri Jul 11 01:49:45 EDT 2025
Mon Jul 21 05:57:48 EDT 2025
Thu Apr 24 22:57:51 EDT 2025
Tue Jul 01 02:37:39 EDT 2025
Wed Jan 22 16:27:29 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords pheomelanin
L-Cystine
L-Glutathione
oral supplementation
skin pigmentation
eumelanin
Language English
License 2021 Wiley Periodicals LLC.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c3297-da8efd67e3311f50c660543d525c7015077966199995984b29224ba85ecf4f2b3
Notes Funding information
This study was fully funded and supported by BCF Life Sciences.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ORCID 0000-0003-1941-4847
PMID 33834608
PQID 2511239792
PQPubID 23479
PageCount 12
ParticipantIDs proquest_miscellaneous_2511239792
pubmed_primary_33834608
crossref_citationtrail_10_1111_jocd_14137
crossref_primary_10_1111_jocd_14137
wiley_primary_10_1111_jocd_14137_JOCD14137
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate February 2022
PublicationDateYYYYMMDD 2022-02-01
PublicationDate_xml – month: 02
  year: 2022
  text: February 2022
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Journal of cosmetic dermatology
PublicationTitleAlternate J Cosmet Dermatol
PublicationYear 2022
References 2009; 22
2019; 9
2013; 26
2007; 127
2019; 5
2013; 88
2014; 27
2011; 33
2008; 35
2006; 19
2003; 16
2019; 18
2011; 14
2005; 27
1996; 107
1993; 101
2016; 55
2004; 134
1989; 93
2019; 80
2015; 28
1997; 109
2013; 79
2017; 10
2011; 42
2003; 25
2003; 28
2016; 60
2016; 82
2010; 3
2005; 37
2012; 23
2016; 9
2009; 17
e_1_2_11_10_1
e_1_2_11_32_1
e_1_2_11_31_1
e_1_2_11_30_1
e_1_2_11_14_1
e_1_2_11_13_1
e_1_2_11_35_1
e_1_2_11_12_1
e_1_2_11_34_1
e_1_2_11_11_1
e_1_2_11_7_1
e_1_2_11_29_1
e_1_2_11_6_1
e_1_2_11_28_1
e_1_2_11_5_1
e_1_2_11_27_1
e_1_2_11_4_1
e_1_2_11_26_1
e_1_2_11_3_1
Nobile V (e_1_2_11_33_1) 2019; 5
Li EPH (e_1_2_11_2_1) 2008; 35
e_1_2_11_21_1
e_1_2_11_20_1
e_1_2_11_25_1
e_1_2_11_24_1
e_1_2_11_9_1
e_1_2_11_23_1
e_1_2_11_8_1
e_1_2_11_22_1
e_1_2_11_18_1
e_1_2_11_17_1
e_1_2_11_16_1
e_1_2_11_15_1
e_1_2_11_19_1
References_xml – volume: 33
  start-page: 210
  issue: 3
  year: 2011
  end-page: 221
  article-title: The melanogenesis and mechanisms of skin‐lightening agents – existing and new approaches
  publication-title: Int J Cosmet Sci
– volume: 27
  start-page: 512
  issue: 4
  year: 2014
  end-page: 524
  article-title: The biology of hyperpigmentation syndromes
  publication-title: Pigment Cell Melanoma Res
– volume: 27
  start-page: 147
  issue: 3
  year: 2005
  end-page: 153
  article-title: Glutathione as a depigmenting agent: an overview
  publication-title: Int J Cosmet Sci
– volume: 23
  start-page: 97
  issue: 2
  year: 2012
  end-page: 102
  article-title: Glutathione as an oral whitening agent: a randomized, double‐blind, placebo‐controlled study
  publication-title: J Dermatol Treat
– volume: 9
  start-page: 22
  issue: 1
  year: 2019
  end-page: 24
  article-title: Risk assessment of “other substances” – L‐cysteine and L‐cystine
  publication-title: Eur J Nutr Food Safety
– volume: 9
  start-page: 325
  year: 2016
  end-page: 332
  article-title: Overall skin tone and skin‐lightening‐improving effects with oral supplementation of lutein and zeaxanthin isomers: a double‐blind, placebo controlled clinical trial
  publication-title: Clin Cosm Invest Dermatol
– volume: 17
  start-page: 14599
  issue: 17
  year: 2009
  end-page: 14617
  article-title: Chromophore concentrations, absorption and scattering properties of human skin
  publication-title: Opt Express
– volume: 127
  start-page: 751
  issue: 4
  year: 2007
  end-page: 761
  article-title: Approaches to identify inhibitors of melanin biosynthesis via the quality control of tyrosinase
  publication-title: J Invest Dermatol
– volume: 37
  start-page: 138
  issue: 2
  year: 2005
  end-page: 143
  article-title: Determination of an optimized conversion matrix for device independent skin color image analysis
  publication-title: Lasers Surg Med
– volume: 19
  start-page: 154
  issue: 2
  year: 2006
  end-page: 162
  article-title: Diversity of pigmentation in cultured human melanocytes is due to differences in the type as well as quantity of melanin
  publication-title: Pigment Cell Res
– volume: 28
  start-page: 520
  issue: 5
  year: 2015
  end-page: 544
  article-title: Melanins and melanogenesis: from pigment cells to human health and technological applications
  publication-title: Pigment Cell Melanoma Res
– volume: 18
  start-page: 728
  issue: 3
  year: 2019
  end-page: 737
  article-title: The clinical effect of glutathione on skin color and other related skin conditions: a systematic review
  publication-title: J Cosmet Dermatol
– volume: 88
  start-page: 76
  issue: 1
  year: 2013
  end-page: 83
  article-title: Mechanisms regulating melanogenesis
  publication-title: An Bra Dermatol
– volume: 26
  start-page: 616
  issue: 5
  year: 2013
  end-page: 633
  article-title: Melanins and melanogenesis: methods, standards, protocols
  publication-title: Pigment Cell Melanoma Res
– volume: 107
  start-page: 698
  issue: 5
  year: 1996
  end-page: 702
  article-title: Cysteine deprivation promotes eumelanogenesis in human melanoma cells
  publication-title: J Invest Dermatol
– volume: 42
  start-page: 231
  issue: 1
  year: 2011
  end-page: 246
  article-title: The oxidative stress‐inducible Cystine/Glutamate antiporter, system X (c) (‐): cystine supplier and beyond
  publication-title: Amino Acids
– volume: 16
  start-page: 487
  issue: 5
  year: 2003
  end-page: 493
  article-title: Rate constants for the first two chemical steps of eumelanogenesis
  publication-title: Pigment Cell Res
– volume: 60
  start-page: 134
  issue: 1
  year: 2016
  end-page: 146
  article-title: L‐Cysteine metabolism and its nutritional implication
  publication-title: Mol Nutr Food Res
– volume: 101
  start-page: 871
  issue: 6
  year: 1993
  end-page: 874
  article-title: Glutathione depletion increases tyrosinase activity in human melanoma cells
  publication-title: J Invest Dermatol
– volume: 14
  start-page: 562
  issue: 6
  year: 2011
  end-page: 568
  article-title: Clinical and nutritional benefits of cysteine‐enriched protein supplements
  publication-title: Curr Opin Clin Nutr Metab Care
– volume: 134
  start-page: 489
  issue: 3
  year: 2004
  end-page: 492
  article-title: Glutathione metabolism and its implication for health
  publication-title: J Nutr
– volume: 10
  start-page: 147
  year: 2017
  end-page: 153
  article-title: Glutathione and its antiaging and antimelanogenic effects
  publication-title: Clin Cosmet Inves. Dermatol
– volume: 28
  start-page: 114
  issue: 2
  year: 2003
  end-page: 116
  article-title: Surface‐reflection elimination in polarization imaging of superficial tissue
  publication-title: Opt Letters
– volume: 25
  start-page: 169
  issue: 4
  year: 2003
  end-page: 181
  article-title: Skin‐lightening products revisited
  publication-title: Int J Cosmet Sci
– volume: 35
  start-page: 444
  year: 2008
  end-page: 449
  article-title: Skin lightening and beauty in four Asian cultures
  publication-title: Adv Consumer Res
– volume: 3
  start-page: 15
  issue: 1‐2
  year: 2010
  end-page: 24
  article-title: Interpreting diffuse reflectance for skin reactions in terms of chromophores
  publication-title: J Biophotonics
– volume: 5
  start-page: 142
  issue: 1
  year: 2019
  end-page: 150
  article-title: Efficacy and safety of L‐Cystine associated or not to a natural keratin (Kera‐Diet ) hydrolysate on hair and nails: randomized, placebo‐controlled, clinical trial on healthy females
  publication-title: J Cosmo Trichol
– volume: 55
  start-page: 153
  issue: 2
  year: 2016
  end-page: 157
  article-title: An open‐label, single‐arm trial of the safety and efficacy of a novel preparation of glutathione as a skin‐lightening agent in Filipino women
  publication-title: Int J Dermatol
– volume: 80
  start-page: 1564
  issue: 6
  year: 2019
  end-page: 1584
  article-title: Developing an international standard for the classification of surface anatomic location for use in clinical practice and epidemiologic research
  publication-title: J Am Acad Dermatol
– volume: 93
  start-page: 100
  issue: 1
  year: 1989
  end-page: 107
  article-title: Analysis of initial melanogenesis including tyrosinase transfer and melanosome differentiation through interrupted melanization by glutathione
  publication-title: J Invest Dermatol
– volume: 109
  start-page: 796
  issue: 6
  year: 1997
  end-page: 800
  article-title: Melanogenesis in cultured melanocytes can be substantially influenced by L‐Tyrosine and L‐Cysteine
  publication-title: J Invest Dermatol
– volume: 79
  start-page: 842
  issue: 6
  year: 2013
  end-page: 846
  article-title: Systemic skin whitening/lightening agents: what is the evidence?
  publication-title: Indian J Dermatol Venereol Leprol
– volume: 82
  start-page: 262
  issue: 3
  year: 2016
  end-page: 272
  article-title: Glutathione as a skin whitening agent: facts, myths, evidence and controversies
  publication-title: Indian J Dermatol Venereol Leprol
– volume: 22
  start-page: 563
  issue: 5
  year: 2009
  end-page: 579
  article-title: Current challenges in understanding melanogenesis: bridging chemistry, biological control, morphology, and function
  publication-title: Pigment Cell Melanoma Res
– ident: e_1_2_11_18_1
  doi: 10.1111/1523-1747.ep12340980
– ident: e_1_2_11_27_1
  doi: 10.1111/ijd.12999
– ident: e_1_2_11_26_1
  doi: 10.3109/09546631003801619
– ident: e_1_2_11_8_1
  doi: 10.1111/j.1755-148X.2009.00610.x
– volume: 35
  start-page: 444
  year: 2008
  ident: e_1_2_11_2_1
  article-title: Skin lightening and beauty in four Asian cultures
  publication-title: Adv Consumer Res
– ident: e_1_2_11_19_1
  doi: 10.4103/0378-6323.179088
– ident: e_1_2_11_3_1
  doi: 10.1002/jbio.200900066
– ident: e_1_2_11_14_1
  doi: 10.1111/1523-1747.ep12365591
– ident: e_1_2_11_20_1
  doi: 10.2147/CCID.S128339
– ident: e_1_2_11_6_1
  doi: 10.1111/j.1468-2494.2010.00616.x
– ident: e_1_2_11_12_1
  doi: 10.1111/1523-1747.ep12277369
– volume: 5
  start-page: 142
  issue: 1
  year: 2019
  ident: e_1_2_11_33_1
  article-title: Efficacy and safety of L‐Cystine associated or not to a natural keratin (Kera‐Diet®) hydrolysate on hair and nails: randomized, placebo‐controlled, clinical trial on healthy females
  publication-title: J Cosmo Trichol
– ident: e_1_2_11_10_1
  doi: 10.1111/j.1600-0749.2006.00293.x
– ident: e_1_2_11_34_1
  doi: 10.9734/EJNFS/2019/45634
– ident: e_1_2_11_31_1
  doi: 10.1111/pcmr.12393
– ident: e_1_2_11_29_1
  doi: 10.1007/s00726-011-0867-5
– ident: e_1_2_11_7_1
  doi: 10.1590/S0365-05962013000100009
– ident: e_1_2_11_32_1
  doi: 10.1111/pcmr.12235
– ident: e_1_2_11_15_1
  doi: 10.1034/j.1600-0749.2003.00082.x
– ident: e_1_2_11_13_1
  doi: 10.1111/1523-1747.ep12371709
– ident: e_1_2_11_16_1
  doi: 10.1002/mnfr.201500031
– ident: e_1_2_11_23_1
  doi: 10.1364/OL.28.000114
– ident: e_1_2_11_35_1
  doi: 10.1111/jocd.12910
– ident: e_1_2_11_5_1
  doi: 10.1038/sj.jid.5700683
– ident: e_1_2_11_25_1
  doi: 10.2147/CCID.S115519
– ident: e_1_2_11_17_1
  doi: 10.1093/jn/134.3.489
– ident: e_1_2_11_22_1
  doi: 10.1016/j.jaad.2018.08.035
– ident: e_1_2_11_4_1
  doi: 10.1364/OE.17.014599
– ident: e_1_2_11_11_1
  doi: 10.4103/0378-6323.120752
– ident: e_1_2_11_28_1
  doi: 10.1097/MCO.0b013e32834c1780
– ident: e_1_2_11_21_1
  doi: 10.1046/j.1467-2494.2003.00182.x
– ident: e_1_2_11_9_1
  doi: 10.1111/j.1467-2494.2005.00235.x
– ident: e_1_2_11_24_1
  doi: 10.1002/lsm.20219
– ident: e_1_2_11_30_1
  doi: 10.1111/pcmr.12121
SSID ssj0017915
Score 2.3633263
Snippet Background Glutathione has become a potential skin‐lightening ingredient after the discovery of its anti‐melanogenic properties. Various mechanisms of action...
Glutathione has become a potential skin-lightening ingredient after the discovery of its anti-melanogenic properties. Various mechanisms of action have been...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 802
SubjectTerms Cystine - therapeutic use
Double-Blind Method
eumelanin
Female
Glutathione - therapeutic use
Humans
L‐Cystine
L‐Glutathione
oral supplementation
pheomelanin
skin pigmentation
Skin Pigmentation - drug effects
Title The effects of the oral supplementation of L‐Cystine associated with reduced L‐Glutathione‐GSH on human skin pigmentation: a randomized, double‐blinded, benchmark‐ and placebo‐controlled clinical trial
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjocd.14137
https://www.ncbi.nlm.nih.gov/pubmed/33834608
https://www.proquest.com/docview/2511239792
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVEBS
  databaseName: EBSCOhost Academic Search Ultimate
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 1473-2165
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017915
  issn: 1473-2130
  databaseCode: ABDBF
  dateStart: 20020901
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVOVD
  databaseName: Journals@Ovid LWW All Open Access Journal Collection Rolling
  customDbUrl:
  eissn: 1473-2165
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017915
  issn: 1473-2130
  databaseCode: OVEED
  dateStart: 20020101
  isFulltext: true
  titleUrlDefault: http://ovidsp.ovid.com/
  providerName: Ovid
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdKJyFeEN-ULxmBkIB5apM0H7xB260a3YqgQ32LnNiBaW1T0uZh-w_5q-DOdt2WdmjwEqWuGye9X3x39u_uCHnp-sKtC5AAjwKXeaIhGBeZz7wEJkJU2NLFAOejY7974h0Om8NK5dcKa6mcJ3vpxda4kv-RKrSBXDFK9h8kay8KDXAO8oUjSBiOV5bxCiEDbUgVcD_DUp2aFr4wCHusdQ5vM5iU3AhkwTsvMHkrfOixA7hXJCPmE8kOvnRxH0GX8JudIdf89Ju9og6RBjUn8vHphV4vFXmZjCRLRpiAUbUk8F99H_PijOl0BLhin-TMsONHMKaNy1TFQy4xlNN8NsZQy7cCtch8bR-gXU5lUXBddjlXu_4fLGcE5kEksXATlvRZTngpVvgMI0BprsnMH8vJOZ_wuSUBDXgKHWQh4Pk1V-lTISX0Kc3Sn1kpASe7blknenL3AI5OQ9em2JNb2oxGcBoryHdWpvdQRYdfqnbyVIDmaegsNuu5vY_78f5JrxcPOsPBq-kPhmXPkB5gasBcIztO4PtOlez0v3Y6bbsRFkSqCIe9TZNhV5HR7HDrNtWGo7TudynDaXCL3DSCpO81fG-TipzcIdePDKfjLvkJKKYGxTTPKKCYIorpHyjG7yyK6RLFFFFMDYrpBoop_FKhmCKK6SqK31FOlxjepesI3qVL_FLoRTfxSxf4pQq_98jJfmfQ6jJTYISlrhMFTPBQZsIPpOs2Glmznvrg3HuuaDrNNMClwCCIwH4FHypqRqGXOBEYvAkPmzLNvMxJ3PukOoGneUhoKASPfPB-Ei_xhIhCN8gCrx5yTzpBlEU18nohojg12fexCMwotl44iDNW4qyRF7bvVOec2drr-ULSMagE3OeDFyIvZzGuGji4X-_UyAMNAXsdXJHy_HpYI28UJv4yQHzYb7XV2aMrDPWY3Fi-c09IdV6U8inY6_PkmcH0byE_9rc
linkProvider Ovid
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+effects+of+the+oral+supplementation+of+L-Cystine+associated+with+reduced+L-Glutathione-GSH+on+human+skin+pigmentation%3A+a+randomized%2C+double-blinded%2C+benchmark-+and+placebo-controlled+clinical+trial&rft.jtitle=Journal+of+cosmetic+dermatology&rft.au=Duperray%2C+Jo%C3%ABl&rft.au=Sergheraert%2C+Renaud&rft.au=Chalothorn%2C+Kunyanatt&rft.au=Tachalerdmanee%2C+Preeyanuch&rft.date=2022-02-01&rft.issn=1473-2165&rft.eissn=1473-2165&rft.volume=21&rft.issue=2&rft.spage=802&rft_id=info:doi/10.1111%2Fjocd.14137&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1473-2130&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1473-2130&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1473-2130&client=summon